drugset / Trial / NCT03060850
A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, dose escalation, phase I study to determine the recommended Phase 2 dose (PR2D) by assessing the DLT, safety and efficacy of AC0010 in patients with B-cell lymphoma.
Timeline
- Start
- 2017-03-17
- Primary completion
- 2019-12-14
- Completion
- 2020-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abivertinib | Small molecule | 200 mg | Oral |
| Subject | Abivertinib | Small molecule | 300 mg | Oral |
| Subject | Abivertinib | Small molecule | 400 mg | Oral |
| Subject | Abivertinib | Small molecule | 500 mg | Oral |